OmniAbOABI
OABI
About: OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Employees: 114
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
243% more call options, than puts
Call options by funds: $120K | Put options by funds: $35K
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0% more funds holding
Funds holding: 163 [Q3] → 163 (+0) [Q4]
14.99% less ownership
Funds ownership: 67.52% [Q3] → 52.53% (-14.99%) [Q4]
33% less capital invested
Capital invested by funds: $334M [Q3] → $225M (-$110M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
153%
upside
Avg. target
$7
343%
upside
High target
$11
596%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Benchmark Robert Wasserman 29% 1-year accuracy 11 / 38 met price target | 280%upside $6 | Buy Reiterated | 12 May 2025 |
RBC Capital Conor McNamara 10% 1-year accuracy 4 / 41 met price target | 153%upside $4 | Outperform Maintained | 27 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 75 / 383 met price target | 596%upside $11 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Based on 8 articles about OABI published over the past 30 days
Neutral
Business Wire
3 days ago
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced its participation in the 21st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today, the company showcased case studies utilizing xPloration, a high-throughput single B-cell screening platform that harnesses machine learning and computer vision artificial intelligence (AI), in a presentation by Bob Chen, Ph.D., Vice President, Discovery Systems, title.
Neutral
Seeking Alpha
1 week ago
OmniAb, Inc. (OABI) Q1 2025 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matthew Foehr - Chief Executive Officer Bob Chen - Vice President, Discovery Systems Conference Call Participants Michael Almisry - Leerink Partners Alexander Xenakis - Truist Securities Joseph Pantginis - H.C. Wainwright Jacqueline Kisa - TD Cowen Operator Good afternoon, and welcome to OmniAb Inc.'s First Quarter 2025 Financial Results and Business Update Conference Call.
Neutral
Zacks Investment Research
1 week ago
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Neutral
Business Wire
1 week ago
OmniAb Reports First Quarter 2025 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. “We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts,” said Matt Foehr, Chief Executive Officer of OmniAb.
Neutral
Business Wire
1 week ago
OmniAb Introduces the xPloration® Partner Access Program
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb's proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence. “xPloration has been a core part of our company'.
Neutral
GlobeNewsWire
1 week ago
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors
Neutral
Business Wire
2 weeks ago
OmniAb to Participate in Five Upcoming Investor Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences over the coming weeks. H.C. Wainwright 1st Annual Royalty Company Virtual Conference, May 13. Management will participate in a fireside chat and a panel discussion on Tuesday, May 13th. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors on Tuesday, May.
Neutral
Business Wire
3 weeks ago
OmniAb Announces Two New Appointments to its Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb's partnership base. These Board changes are effective immediately and increase the number of Directo.
Neutral
Seeking Alpha
1 month ago
OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kripa Devarakonda - Truist Securities Operator Good afternoon and welcome to OmniAb Inc's Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference call.
Negative
Zacks Investment Research
1 month ago
OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago.
Charts implemented using Lightweight Charts™